{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:22:48Z","timestamp":1783416168999,"version":"3.54.6"},"reference-count":38,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The aim of this multicenter retrospective study was to assess the change in liver function in patients with hepatocellular carcinoma treated with lenvatinib. Among 139 consecutive patients receiving lenvatinib treatment between March 2018 and July 2019, 28 patients with Child-Pugh class B and one patient with inadequate patient information were excluded. Remaining 110 patients with Child-Pugh class A were analyzed. The median age of 110 patients was 73 years (IQR 66.7\u201380) and 88 patients (80.0%) were men. Child-Pugh score was 5 (CP5A) and 6 (CP6A) in 58 (52.7%) and 52 patients (47.3%), and ALBI grade was 1 and 2 in 38 (34.5%) and 72 patients (65.5%), respectively. The deterioration to Child-Pugh class B was found in 43 patients (39.1%) during the lenvatinib treatment. The favorable factors related to preserving liver function were significantly shown to be male, ALBI grade 1, CP5A and BCLC early or intermediate stage in the multivariate analysis. The formation of ascites was found in 32 patients (28.6%). The significant unfavorable factors associated with the formation of ascites were found to be low platelet count and CP6A. Among the 79 patients, there were 36 (45.6%) and 11 patients (13.9%) who fulfilled the criteria for candidate for the post-progression treatment and ramucirumab treatment, respectively. The predictive factors of the post-progression treatment were shown to be ALBI grade 1 and CP5A in multivariate analysis. In conclusion, male, ALBI grade 1, CP5A and BCLC early or intermediate stage were favorable factors related to sustaining liver function and the patients with ALBI grade 1 and CP5A were eligible for the post-progression treatment. Careful screening for ascites was needed in patients with low platelet count and CP6A.<\/jats:p>","DOI":"10.3390\/cancers12102906","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T21:42:21Z","timestamp":1602798141000},"page":"2906","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-285X","authenticated-orcid":false,"given":"Takeshi","family":"Hatanaka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishindenmachi, Maebashi, Gunma 371-0821, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan"},{"name":"Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, 36 Takamatsu-cho, Takasaki, Gunma 370-0829, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamon","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Shibukawa Medical Center, 383 Shirai, Shibukawa, Gunma 377-0280, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kiryu Kosei General Hospital, 6-6-3 Orihime-cho, Kiryu, Gunma 376-0024, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isesaki Municipal Hospital, 12-1 Tsunatorihonmachi, Isesaki, Gunma 372-0817, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tojima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Maebashi Red Cross Hospital, 389-1 Asakuramachi, Maebashi, Gunma 371-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-0102","authenticated-orcid":false,"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, 36 Takamatsu-cho, Takasaki, Gunma 370-0829, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Maebashi Red Cross Hospital, 389-1 Asakuramachi, Maebashi, Gunma 371-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Harimoto","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-4331","authenticated-orcid":false,"given":"Toshio","family":"Uraoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): Second interim analysis","volume":"68","author":"Lencioni","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/liv.12591","article-title":"Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: A large multicenter study in Japan","volume":"35","author":"Takeda","year":"2015","journal-title":"Liv. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2169\/internalmedicine.1594-18","article-title":"Impact of the prognostic nutritional index on the survival of Japanese patients with hepatocellular carcinoma treated with sorafenib: A multicenter retrospective study","volume":"58","author":"Hatanaka","year":"2019","journal-title":"Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/cam4.1909","article-title":"Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1002\/cam4.2241","article-title":"Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Cancer Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ueshima, K., Nishida, N., Hagiwara, S., Aoki, T., Minami, T., Chishina, H., Takita, M., Minami, Y., Ida, H., and Takenaka, M. (2019). Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: A multicenter study. Cancers, 11.","DOI":"10.3390\/cancers11070952"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hepr.13460","article-title":"Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study","volume":"50","author":"Hatanaka","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000502095","article-title":"Early relative change in hepatic function with lenvatinib for unresectable hepatocellular carcinoma","volume":"97","author":"Hiraoka","year":"2019","journal-title":"Oncology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000503031","article-title":"Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib","volume":"9","author":"Hiraoka","year":"2020","journal-title":"Liv. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/hep.510250102","article-title":"The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin, and nitric oxide","volume":"25","author":"Rockey","year":"1997","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2007.03.014","article-title":"Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers","volume":"47","author":"Bosch","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_20","first-page":"G416","article-title":"Nitric oxide modulates hepatic vascular tone in normal rat liver","volume":"267","author":"Mittal","year":"1994","journal-title":"Am. J. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/0016-5085(93)90655-V","article-title":"Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats","volume":"104","author":"Sieber","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0016-5085(99)70408-7","article-title":"Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat","volume":"117","author":"Shah","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jhep.2005.04.002","article-title":"VEGF-induced angiogenesis drives collateral circulation in portal hypertension","volume":"43","author":"Moreau","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10637-017-0507-3","article-title":"Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment","volume":"36","author":"Ogasawara","year":"2018","journal-title":"Invest. New Drugs."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/hepr.13180","article-title":"Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice","volume":"48","author":"Uchikawa","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/jjco\/hyy153","article-title":"Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma","volume":"49","author":"Yukimoto","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Takada, H., Kurosaki, M., Tsuchiya, K., Komiyama, Y., Itakura, J., Takahashi, Y., Nakanishi, H., Yasui, Y., Tamaki, N., and Maeyashiki, C. (2019). Baseline and early predictors of good patient candidates for second-line after sorafenib treatment in unresectable hepatocellular carcinoma. Cancers, 11.","DOI":"10.3390\/cancers11091256"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/hepr.13358","article-title":"Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment","volume":"49","author":"Kuzuya","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1200\/JCO.2017.73.8245","article-title":"Starting dose of sorafenib for the treatment of hepatocellular carcinoma: A retrospective, multi-institutional study","volume":"35","author":"Reiss","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Eso, Y., Nakano, S., Mishima, M., Arasawa, S., Iguchi, E., Nakamura, F., Takeda, H., Takai, A., Takahashi, K., and Taura, K. (2019). Dose intensity\/body surface area ratio is a novel marker useful for predicting response to lenvatinib against hepatocellular carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12010049"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sasaki, R., Fukushima, M., Haraguchi, M., Miuma, S., Miyaaki, H., Hidaka, M., Eguchi, S., Matsuo, S., Tajima, K., and Matsuzaki, T. (2019). Response to lenvatinib is associated with optimal relative dose intensity in hepatocellular carcinoma: Experience in clinical settings. Cancers, 11.","DOI":"10.3390\/cancers11111769"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","article-title":"Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma","volume":"67","author":"Cabibbo","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: An update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000492534","article-title":"Ramucirumab as second-line systemic therapy in hepatocellular carcinoma","volume":"7","author":"Kudo","year":"2018","journal-title":"Liv. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2906\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:19:11Z","timestamp":1760177951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cancers12102906"],"URL":"https:\/\/doi.org\/10.3390\/cancers12102906","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]}}}